MDxHealth's Q3 revenue misses expectations due to disrupted commercial execution
MDXH•MDxHealth reported Q3 revenue of $22.71 million, below the $28.75 million analyst consensus, while net loss widened 26% year over year to $12.26 million. The company cited sales team turnover and commercial restructuring, and aims to return to growth in 2027.
1. Quarterly results
MDxHealth's Q3 revenue was flat year over year at $22.71 million, missing the $28.75 million consensus estimate from five analysts. Net loss widened 26% to $12.26 million, while operating loss increased 86% to $8.13 million.
2. Execution and outlook
The company said accelerated turnover in its sales organization disrupted commercial execution during the quarter. Higher operating expenses related to the ExoDx acquisition in September 2025 contributed to the operating loss, while a lower proportion of tissue-based tests in the revenue mix reduced gross margin. MDxHealth expects to exit Q4 with a fully staffed and trained sales organization, aims to return to growth in 2027, and plans to roll out strategic AI initiatives in the first half of 2027.
